Time filter

Source Type

Prahran, Australia

Dearnaley D.P.,Institute of Cancer Research | Jovic G.,University College London | Syndikus I.,Clatterbridge Center for Oncology | Khoo V.,Royal Marsden NHS Foundation Trust | And 13 more authors.
The Lancet Oncology | Year: 2014

Background: The aim of this trial was to compare dose-escalated conformal radiotherapy with control-dose conformal radiotherapy in patients with localised prostate cancer. Preliminary findings reported after 5 years of follow-up showed that escalated-dose conformal radiotherapy improved biochemical progression-free survival. Based on the sample size calculation, we planned to analyse overall survival when 190 deaths occurred; this target has now been reached, after a median 10 years of follow-up. Methods: RT01 was a phase 3, open-label, international, randomised controlled trial enrolling men with histologically confirmed T1b-T3a, N0, M0 prostate cancer with prostate specific antigen of less than 50 ng/mL. Patients were randomly assigned centrally in a 1:1 ratio, using a computer-based minimisation algorithm stratifying by risk of seminal vesicle invasion and centre to either the control group (64 Gy in 32 fractions, the standard dose at the time the trial was designed) or the escalated-dose group (74 Gy in 37 fractions). Neither patients nor investigators were masked to assignment. All patients received neoadjuvant androgen deprivation therapy for 3-6 months before the start of conformal radiotherapy, which continued until the end of conformal radiotherapy. The coprimary outcome measures were biochemical progression-free survival and overall survival. All analyses were done on an intention-to-treat basis. Treatment-related side-effects have been reported previously. This trial is registered, number ISRCTN47772397. Findings: Between Jan 7, 1998, and Dec 20, 2001, 862 men were registered and 843 subsequently randomly assigned: 422 to the escalated-dose group and 421 to the control group. As of Aug 2, 2011, 236 deaths had occurred: 118 in each group. Median follow-up was 10·0 years (IQR 9·1-10·8). Overall survival at 10 years was 71% (95% CI 66-75) in each group (hazard ratio [HR] 0·99, 95% CI 0·77-1·28; p=0·96). Biochemical progression or progressive disease occurred in 391 patients (221 [57%] in the control group and 170 [43%] in the escalated-dose group). At 10 years, biochemical progression-free survival was 43% (95% CI 38-48) in the control group and 55% (50-61) in the escalated-dose group (HR 0·69, 95% CI 0·56-0·84; p=0·0003). Interpretation: At a median follow-up of 10 years, escalated-dose conformal radiotherapy with neoadjuvant androgen deprivation therapy showed an advantage in biochemical progression-free survival, but this advantage did not translate into an improvement in overall survival. These efficacy data for escalated-dose treatment must be weighed against the increase in acute and late toxicities associated with the escalated dose and emphasise the importance of use of appropriate modern radiotherapy methods to reduce side-effects. Funding: UK Medical Research Council. © 2014 Dearnaley et al. Open Access article distributed under the terms of CC BY. Source

Soh S.E.,Alfred Health
Rural and remote health | Year: 2012

The motor and non-motor symptoms associated with idiopathic Parkinson's disease (PD) may compromise the health-related quality of life (HRQOL) of some individuals living with this debilitating condition. Although growing evidence suggests that PD may be more prevalent in rural communities, there is little information about the life quality of these individuals. This study examines whether HRQOL ratings vary in relation to rural and metropolitan life settings. An analytic cross-sectional study was conducted to compare the HRQOL of two separate samples of people with PD living in metropolitan Melbourne and rural Victoria. The metropolitan sample consisted of 210 individuals who had participated in the baseline assessment for an existing clinical trial. The rural sample comprised 24 participants who attended community-based rehabilitation programs and support groups in rural Victoria. Health-related quality of life was quantified using the Parkinson's Disease Questionnaire-39 (PDQ-39). The HRQOL of participants in rural Australia differed from individuals living in a large metropolitan city (p=0.025). Participants in rural Australia reported worse overall HRQOL, after controlling for differences in disease duration. Their overall HRQOL was lower than for city dwellers. Rural living was also found to be a significant negative predictor of HRQOL (β=0.14; 95% CI -1.27 to -0.08; p=0.027). The findings of this study suggest that some people with PD living in rural Victoria perceive their HRQOL to be relatively poor. In order to minimise the debilitating consequences of this disease, further studies examining the factors that may contribute to the HRQOL of individuals living in rural and remote areas are required. Source

A method for diagnosing acute coronary syndrome (ACS) in a subject, the method comprising measuring plasma macrophage migration inhibitory factor (MIF) concentration in a sample from the subject, and diagnosing ACS when the subject plasma MIF concentration is greater than a reference plasma MIF concentration, wherein the sample is taken less than 4 hours after symptom onset. The invention also relates to a method for prognosing ACS in a subject, the method comprising measuring plasma MIF concentration in a sample from the subject, diagnosing ACS when the subject plasma MIF concentration is greater than a reference plasma MIF concentration, and prognosing the magnitude of ACS from the subject plasma MIF concentration. Also provided is a method of treating ACS in a subject, a device, a kit, and a cardiac biomarker related to the methods of diagnosing and prognosing ACS.

Alfred Health | Date: 2012-05-30

A bone splint manufactured in a polylactide copolymer, the splint comprising an elongate bridging member adapted to be secured to and across fractured bone ends and means to reduce the effective length of the bridging member so that, in use, the splint holds the bone ends together.

News Article | September 12, 2016
Site: http://www.rdmag.com/rss-feeds/all/rss.xml/all

The spheroid is the width of a few human hairs and made up of 25,000 human lung cells clustered together with iron particle, suspended in a fluid that runs though a microscopic obstacle course of channels sealed between glass. It is a science fiction-like biological machine and testing ground housed "on-a-chip" that is being developed by University of Melbourne scientists in a bid to monitor human tissue in an environment that mimics the mechanics inside our bodies, including the mechanics of breathing. The project could help radically improve how we test whether a new drug will work and in the process save the medical industry hundreds of millions of dollars a year. Using magnets the scientists plan to manipulate the iron particles and stretch the lung tissue by dragging the spheroid around corners and squeezing it down corridors. And by using quantum physics the scientists will be able to watch how drugs interact with healthy and diseased cells. Underneath the glass they plan to place a thin sheet of diamond, the structure of which has been modified with atomic defects that can be used to image the magnetic fields cast by the embedded iron particles, effectively imaging the cells themselves. "What we are trying to do is add another level of reality to drug testing," said the University's Prof. Alastair Stewart, a pharmacologist at the Faculty of Medicine, Dentistry and Health Science and co-director of the Lung Health Research Centre. "This three-dimensional chip environment is a softer environment than the two dimensional plastic environment we currently use to test human tissue cultures, and in mechanical terms is more similar to a human body. So we are aiming to replicate the environment of the cells in the disease as it occurs in our bodies." Pharmaceutical development depends on mouse models or on two-dimensional cultures for testing the potential effectiveness of a drug before progressing to expensive human trials. But these tests are failing to identify the many drugs that go on to fail when finally tested in humans. A review of pharmaceutical giant Astra-Zeneca's portfolio performance between 2005 and 2010 suggests that failure rates when testing for effectiveness in humans can be as high as 85 per cent. The wasted money can range from $10 million to $100 million per failed drug. But by introducing drugs to human tissue inside the three-dimensional obstacle course and monitoring what happens, researchers aim to be able to better determine whether a drug can work or not before ever having to undertake expensive human trials. In this case the researchers are working on pulmonary fibrosis, a disease in which lung tissue is scarred and stiffens making it difficult to breathe. It is a progressive and fatal disease for which we don't know the cause, but is linked to smoking. "There is significant unmet need for new drugs to be developed that can combat this fatal lung condition," Associate Professor Glen Westall, a leading lung fibrosis expert at Alfred Health and a partner investigator on the research. Through the University's cross-disciplinary Hallmark research initiatives, Professor Stewart has teamed with bioengineers and quantum physicists to work with Australian-based global biopharmaceutical company CSL Limited in developing the "micro-tissue on a chip" model. They plan to use it to test a series of different anti-fibrotics in what would be the first systematic benchmarking of whether such models can accurately fail ineffective drugs. The research team is focusing on fibroblast cells that form the connective tissue in our bodies and which, when fibrosis occurs, produce too much of the connective "glue" that binds tissue and therefore causes it to stiffen. By being able to move a spheroid of diseased fibroblasts through the corridors on the chip and use the magnets to replicate breathing, the researchers will be able to monitor what is going on at a cellular level when the tissue stiffens. The lung cells are made available through collaboration with Alfred Health and Donate Life. Diseased lung cells are harvested from patients with lung fibrosis who have undergone a lung transplant, and healthy cells come from donor lungs that for various reasons haven't been suitable for a transplant. Technology to create tissue and organs "on-a-chip" is at the forefront of medical research aimed at replicating what is going on in our bodies. But so far, while researchers around the world have been working to perfect the action of whole organs in a micro-fluidic chip environment, Stewart said the accuracy of such models in being able to "fail" potential drugs is yet to be proven. "There are many aspects of organ-on-a-chip technology that remain a matter of belief rather than of evidence," he said. Rather than trying to replicate a whole organ-on-a-chip, such as a lung, bioengineer Prof. Peter Lee said the project is focused on creating a testing system specifically adapted to the area they want to test, in this case lung fibroblasts. "It is like creating an obstacle course that has some specific meaning to it," said Lee from the Department of Mechanical Engineering at the University of Melbourne. "We are developing it in conjunction with what we want to test, rather than trying to develop the most ideal whole organ we can and then working out what we can do with it." Critical to the project will be the ability of the researchers to "see" at high magnification what is going on in the spheroid as it is put through the obstacle course and interacts with drugs. That is where the quantum physics comes in. In 2013 University of Melbourne physicist Prof. Lloyd Hollenberg won the Victoria Prize for his work in using quantum physics to create nano-scale sensors. These sensors are the size of a single atom embedded in diamond crystal, and when engineered as a two dimensional grid just below a diamond surface they can image magnetic fields at resolutions a million times better than traditional magnetic resonance imaging (MRI). Crucially, the imaging can be done without exposing the tissue to direct light that would be toxic for the cells. "Alastair needed a non-invasive way of measuring the magnetic fields within the spheroid," said Hollenberg, the Thomas Baker Chair at the School of Physics. "By bringing the light in at an angle onto the diamond, the light only goes into the sensors and reflects back. It doesn't enter the tissue." The imaging technique uses a thin sheet of synthetic diamond crystal about four millimetres square. To create the sensors the researchers remove two carbon atoms from the usual diamond structure, replacing them with one nitrogen atom and leaving an atomic space, or vacancy, where the other carbon atom should be. The combination of the nitrogen atom, the vacancy and an additional electron creates the so-called Nitrogen Vacancy (NV) defect, which acts as the sensor. When green light is shone onto the diamond surface the NV defects reflect back red light, the strength of which is dependent on the local magnetic field. In addition the NV defects can be put into a quantum state, i.e. it can exist in two energy states at once – grounded and excited. Once in this state of "superposition" the NV is highly sensitive to picking up any magnetic fields around it. When the tissue chip is placed on the diamond-imaging chip, the NVs will pick up the magnetic fields of iron particles embedded on the cells. Using the variation in the power of the red light reflected back, the scientists will pinpoint the source of the magnetic field and therefore image the cells. "By imaging the position of the beads using their magnetic fields, and then moving the beads to mimic actions like breathing, we can watch what is happening and how stiff or soft the cells and tissue may become in response to drugs," said David Simpson, Ph.D., research fellow in quantum physics at the School of Physics who has built the quantum sensor microscope system. Ultimately Professor Hollenberg wants to take the imaging technique further down in scale to be able to image the single proteins in cells that regulate our tissues and organs. That could allow us to accurately understand and predict how a drug or a potential drug will work in the body. "What we want to do is position a protein or other bio-molecule on our sensor surface and use the quantum imaging system like a nano-MRI machine and find out exactly what the shape is, because that shape tells you a lot about how a drug will interact with it."

Discover hidden collaborations